Look for:

Our offer for

TAKEDA PHARMACEUTICAL CORP LTD.


ISIN:
JP3463000004
WKN:
4502

2024/06/20 08:00:00
Price
4,023.00 JPY
Difference 0.00% (0.00)

General attributes

ISINJP3463000004
Symbol4502
ExchangeTokyo Stock Exchange
CurrencyJPY
SectorChemical / Pharmaceutical / Health
Security typeStock
Market cap (m)37,185 EUR
BenchmarkNIKKEI 225

Market data

Bid (Bid size)4,018.00 JPY (400)
Ask (Ask size)4,023.00 JPY (400)
Open4,005.00 JPY
High4,033.00 JPY
Low4,004.00 JPY
Close (prev. day)4,023.00 JPY
VWAP4,017.675 JPY
Volume (pcs)3,082,800
Trading volume123,856,885.00
Number of trades3,294
Last size836,500

Futures and Options

Related Futures-
Related Options-

PDF Downloads

Company report: TAKEDA PHARMACEUTICAL CORP LTD.PDF Download

Scale: ABS REL         Instrument
Interactive chart

Add Benchmark:



Information about previous performance does not guarantee future performance.
Source: FactSet

Recent research

Date Headline Download
2024/06/14 en Global Equity Ratings PDF Download
2024/05/29 en Global Equity Ratings PDF Download
2024/04/26 en Global Equity Ratings PDF Download
2024/04/03 en Global Equity Ratings PDF Download
2024/03/13 en Global Equity Ratings PDF Download


2024/06/20 08:00:00
Price
4,023.00 JPY
Difference 0.00% (0.00)

General attributes

ISINJP3463000004
Symbol4502
ExchangeTokyo Stock Exchange
CurrencyJPY
SectorChemical / Pharmaceutical / Health
Security typeStock
Market cap (m)37,185 EUR
BenchmarkNIKKEI 225

Market data

Bid (Bid size)4,018.00 JPY (400)
Ask (Ask size)4,023.00 JPY (400)
Open4,005.00 JPY
High4,033.00 JPY
Low4,004.00 JPY
Close (prev. day)4,023.00 JPY
VWAP4,017.675 JPY
Volume (pcs)3,082,800
Trading volume123,856,885.00
Number of trades3,294
Last size836,500

Performance and Risk

6m1Y3Y
Perf (%)+0.68%-12.47%+8.06%
Perf (abs.)+27.00-573.00+300.00
Beta0.320.400.46
Volatility16.6017.6617.77
Scale: ABS REL         Instrument
Interactive chart

Add Benchmark:



Information about previous performance does not guarantee future performance.
Source: FactSet

Price data

Ø price 5 days | Ø volume 5 days (pcs.)4,079.80 JPY (4,380,480)
Ø price 30 days | Ø volume 30 days (pcs.)4,146.70 JPY (3,701,353)
Ø price 100 days | Ø volume 100 days (pcs.)4,224.56 JPY (4,219,982)
Ø price 250 days | Ø volume 250 days (pcs.)4,309.61 JPY (4,136,185)
YTD High | date4,494.00 JPY (2024/02/27)
YTD Low | date4,003.00 JPY (2024/06/19)
52 Weeks High | date4,873.00 JPY (2023/09/15)
52 Weeks Low | date3,900.00 JPY (2023/12/18)

All listings for TAKEDA PHARMACEUTICAL CORP LTD.

Exchange  DateTimePriceTrading volume (mio.)Number of trades
Berlin2024/06/2008:0823.56 EUR0.003
Duesseldorf2024/06/2019:3123.38 EUR0.007
FINRA other OTC Issues2024/06/2015:3024.48 USD13.516
Frankfurt2024/06/2021:5023.43 EUR0.011
Fukuoka Stock Exchange2024/04/1702:254,080.00 JPY0.001
Hamburg2024/06/2008:0023.37 EUR0.003
Hanover2024/06/2008:0823.36 EUR0.003
London Stock Exchange2019/03/2612:2837.59 EUR0.001
Munich2024/06/2008:1723.79 EUR0.002
Sapporo Stock Exchange2024/03/1101:534,300.00 JPY0.012
Stuttgart2024/06/2008:0723.45 EUR0.003
Tokyo Stock Exchange2024/06/2008:004,023.00 JPY123.863,294
Tradegate2024/06/2022:2623.60 EUR0.0210
Vienna Stock Exchange2024/06/2017:3223.66 EUR0.002

Company Logo

https://gateway.mdgms.com/extern/logo_image.html?ID_LOGO=3100&ID_TYPE_IMAGE_LOGO=2

Contact Details

TAKEDA PHARMACEUTICAL CO. LTD.
- -
4-1-1 Dosho-machi, Chuo-Ku - 540-8645 Osaka
Telefon: +81-6-6204-2111
Fax: +81-6-6204-2880
E-mail: -

PDF Downloads

Company report: TAKEDA PHARMACEUTICAL CORP LTD.PDF Download

Company Profile

Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other. The Prescription Drugs segment includes the manufacture and sale of pharmaceutical products. The Consumer Healthcare segment includes the manufacture and sale of OTC drugs and quasi-drugs. The Other segment includes manufacture and sale of reagents, clinical diagnostics, and chemical products. The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan.

Members of Management Board

Christophe WeberChairman of Managing Board
Andrew PlumpMember of Executive Committee
Costa SaroukosMember of Executive Committee
Gabriele RicciMember of Executive Committee
Giles PlatfordMember of Executive Committee
Julie KimMember of Executive Committee
Koki SatoMember of Executive Committee
Lauren DupreyMember of Executive Committee
Marcello AgostiMember of Executive Committee
Milano FurutaMember of Executive Committee
Mwana LugogoMember of Executive Committee
Ramona SequeiraMember of Executive Committee
Takako OhyabuMember of Executive Committee
Teresa BitettiMember of Executive Committee
Thomas WozniewskiMember of Executive Committee
Yoshihiro NakagawaMember of Executive Committee

Board of directors

Masami IijimaChairman of Supervisory Board
Andrew PlumpMember of Supervisory Board
John MaraganoreMember of Supervisory Board
Steven GillisMember of Supervisory Board
Constantine SaroukosMember of Supervisory Board
Emiko HigashiMember of Supervisory Board
Ian ClarkMember of Supervisory Board
Jean-Luc ButelMember of Supervisory Board
Kimberly ReedMember of Supervisory Board
Koji HatsukawaMember of Supervisory Board
Michel OrsingerMember of Supervisory Board
Miki TsusakaMember of Supervisory Board
Yoshiaki FujimoriMember of Supervisory Board





Decline
Accept

We use cookies and web analysis software to give you the best possible experience on our website. If you consent, these tools will be used. Please read more information here

INFORMATION FOR PRIVATE CLIENTS / CONSUMERS

Any information, material and services regarding financial instruments and securities provided by Česká spořitelna/Erste Group/ or any of its affiliates (collectively “Erste Group“) on this and any linked website hereafter (jointly the “Websites“) shall be exclusively to investors who are not subject to any legal sale or purchase restrictions.

By agreeing to this hereto, the visitor entering this Websites confirms that has read, understood and accepted this Information and the Disclaimer